{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:52:08Z","timestamp":1790805128245,"version":"4.1.0"},"reference-count":100,"publisher":"Informa UK Limited","issue":"17","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2023,11,22]]},"DOI":"10.1080\/14656566.2023.2257604","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:54:08Z","timestamp":1694404448000},"page":"1887-1899","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":44,"title":["The complement system: a novel therapeutic target for age-related macular degeneration"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6664-8211","authenticated-orcid":false,"given":"Aumer","family":"Shughoury","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duriye D.","family":"Sevgi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-6777","authenticated-orcid":false,"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Clearside Biomedical, Inc, Alpharetta, GA, USA"},{"name":"Midwest Eye Institute, Carmel, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.1.47"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.4.514"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S185052"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(05)80070-5"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9580"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)00169-5"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010329"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(89)32694-7"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1988.106"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004397-200404440-00004"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505043321806"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.208"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00265-2"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes13071233"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.03.002"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(00)00140-5"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2009.11.003"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2014.11.005"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068883"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00015"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2620"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00764"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00431-y"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12468"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60228-X"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.145.2.357"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2015.04.006"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60042-5"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-71767-8_7"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02627.x"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2010.05.007"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1350-9462(01)00010-6"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25557-8"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109557"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2020.10.008"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-090413-025610"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1575358"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100936"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwr025"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.07.011"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.6068"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.02.025"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.10.012"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003798"},{"key":"e_1_3_4_48_1","first-page":"1500","article-title":"Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies","volume":"63","author":"Goldberg R","year":"2022","unstructured":"Goldberg R, Heier JS, Wykoff CC, et al. Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. Invest Ophthalmol Visual Sci. 2022;63:1500.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_49_1","article-title":"Apellis announces 24-month results showing increased effects over time with pegcetacoplan in Phase 3 DERBY and OAKS studies in geographic atrophy (GA) [Internet]","author":"Apellis Pharmaceuticals, Inc","year":"2022","unstructured":"Apellis Pharmaceuticals, Inc. Apellis announces 24-month results showing increased effects over time with pegcetacoplan in Phase 3 DERBY and OAKS studies in geographic atrophy (GA) [Internet]. Apellis. 2022 [cited 2023 Mar 2]. Available from: https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-announces-24-month-results-showing-increased-effects","journal-title":"Apellis"},{"key":"e_1_3_4_50_1","article-title":"Apellis presents Phase 3 functional analyses of SYFOVRETM (pegcetacoplan injection) for geographic atrophy - apellis Pharmaceuticals, Inc","author":"Apellis Pharmaceuticals, Inc","year":"2023","unstructured":"Apellis Pharmaceuticals, Inc. Apellis presents Phase 3 functional analyses of SYFOVRETM (pegcetacoplan injection) for geographic atrophy - apellis Pharmaceuticals, Inc [Interne] Apellis Pharm. 2023 [cited 2023 Apr 29]. Available from: https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-presents-phase-3-functional-analyses-syfovretm","journal-title":"Apellis Pharm"},{"key":"e_1_3_4_51_1","article-title":"Apellis provides updates on injection kits and rare safety events with SYFOVRE\u00ae (pegcetacoplan injection) - apellis Pharmaceuticals, Inc","author":"Apellis Pharmaceuticals, Inc","year":"2023","unstructured":"Apellis Pharmaceuticals, Inc. Apellis provides updates on injection kits and rare safety events with SYFOVRE\u00ae (pegcetacoplan injection) - apellis Pharmaceuticals, Inc [Internet]. Apellis Pharm. 2023 [cited 2023 Aug 31]. Available from: https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-provides-updates-injection-kits-and-rare-safety-events","journal-title":"Apellis Pharm"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.08.018"},{"key":"e_1_3_4_53_1","article-title":"NGM bio announces topline results from the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration [Internet]","author":"NGM Biopharmaceuticals, Inc","year":"2022","unstructured":"NGM Biopharmaceuticals, Inc. NGM bio announces topline results from the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration [Internet]. NGM Bio. 2022 [cited 2023 Feb 28]. Available from: https:\/\/ir.ngmbio.com\/news-releases\/news-release-details\/ngm-bio-announces-topline-results-catalina-phase-2-trial-ngm621\/","journal-title":"NGM Bio"},{"key":"e_1_3_4_54_1","article-title":"NGM bio announces presentation of post-hoc analyses from CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at the retina society annual scientific meeting [Internet]","author":"NGM Biopharmaceuticals, Inc","year":"2022","unstructured":"NGM Biopharmaceuticals, Inc. NGM bio announces presentation of post-hoc analyses from CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at the retina society annual scientific meeting [Internet]. NGM Bio. 2022 [cited 2023 Feb 28]. Available from: https:\/\/ir.ngmbio.com\/news-releases\/news-release-details\/ngm-bio-announces-presentation-post-hoc-analyses-catalina-phase\/","journal-title":"NGM Bio"},{"key":"e_1_3_4_55_1","first-page":"183","article-title":"KNP-301, a dual inhibitor of the complement pathway and angiogenesis, effectively suppresses angiogenesis and atrophy","volume":"62","author":"Chung ED","year":"2021","unstructured":"Chung ED (Philip), Kim D, Ryu S, et al. KNP-301, a dual inhibitor of the complement pathway and angiogenesis, effectively suppresses angiogenesis and atrophy. Invest Ophthalmol Visual Sci. 2021;62:183. (Philip).","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_56_1","unstructured":"Blouse GE. CB 2782-PEG: a complement factor C3- inactivating protease and potential long-acting treatment for dry AMD [Internet]. 2019 [cited 2023 Feb 25]. Available from: https:\/\/www.catalystbiosciences.com\/wp-content\/uploads\/2021\/05\/Blouse_CBDD_20191115_vF.pdf"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01624-0"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1999.0798"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/annotation\/32b9bc31-ed6d-4d31-9ce0-480407017bad"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408835103"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.044"},{"key":"e_1_3_4_62_1","first-page":"3433","article-title":"Generation and characterization of LFG316, a fully-human anti-C5 antibody for the treatment of age-related macular degeneration","volume":"55","author":"Roguska M","year":"2014","unstructured":"Roguska M, Splawski I, Diefenbach-Streiber B, et al. Generation and characterization of LFG316, a fully-human anti-C5 antibody for the treatment of age-related macular degeneration. Invest Ophthalmol Visual Sci. 2014;55:3433.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_63_1","article-title":"Anti-complement C5 monotherapy ineffective in reducing geographic atrophy lesion size","author":"Sherrer K","year":"2016","unstructured":"Sherrer K, Kahl K. Anti-complement C5 monotherapy ineffective in reducing geographic atrophy lesion size. Ocular Surg News [Internet]. 2016 Feb 15 [cited 2023 Apr 29]. Available from: https:\/\/www.healio.com\/news\/ophthalmology\/20160215\/anticomplement-c5-monotherapy-ineffective-in-reducing-geographic-atrophy-lesion-size","journal-title":"Ocular Surg News"},{"key":"e_1_3_4_64_1","first-page":"4986","article-title":"A proof of concept study of intravitreal (IVT) LFG316 in patients with neovascular age realted macular degeneration (nAMD)","volume":"57","author":"Gallemore RP","year":"2016","unstructured":"Gallemore RP, Elman MJ, Milton M, et al. A proof of concept study of intravitreal (IVT) LFG316 in patients with neovascular age realted macular degeneration (nAMD). Invest Ophthalmol Visual Sci. 2016;57:4986.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.027"},{"key":"e_1_3_4_66_1","first-page":"1","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial","author":"Patel SS","year":"2023","unstructured":"Patel SS, Lally DR, Hsu J, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye. 2023;1\u20137.","journal-title":"Eye"},{"key":"e_1_3_4_67_1","article-title":"Iveric bio announces positive topline data from Zimura\u00ae GATHER2 Phase 3 clinical trial in geographic atrophy [Internet]","author":"Iveric Bio, Inc","year":"2022","unstructured":"Iveric Bio, Inc. Iveric bio announces positive topline data from Zimura\u00ae GATHER2 Phase 3 clinical trial in geographic atrophy [Internet]. Iveric Bio. 2022 [cited 2023 Feb 28]. Available from: https:\/\/investors.ivericbio.com\/news-releases\/news-release-details\/iveric-bio-announces-positive-topline-data-zimurar-gather2-phase","journal-title":"Iveric Bio"},{"key":"e_1_3_4_68_1","first-page":"984","article-title":"Treatment response to avacincaptad pegol by baseline patient characteristics: a prespecified subgroup analysis of the phase 3 GATHER2 study","volume":"64","author":"Danzig CJ","year":"2023","unstructured":"Danzig CJ, Kaiser P, Lally D, et al. Treatment response to avacincaptad pegol by baseline patient characteristics: a prespecified subgroup analysis of the phase 3 GATHER2 study. Invest Ophthalmol Visual Sci. 2023;64:984.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_69_1","article-title":"Iveric bio announces vision loss reduction data in geographic atrophy from avacincaptad pegol GATHER trials [Internet]","author":"Iveric Bio, Inc","year":"2023","unstructured":"Iveric Bio, Inc. Iveric bio announces vision loss reduction data in geographic atrophy from avacincaptad pegol GATHER trials [Internet]. Business Wire. 2023 [cited 2023 Aug 20]. Available from: https:\/\/www.businesswire.com\/news\/home\/20230228006487\/en\/Iveric-Bio-Announces-Vision-Loss-Reduction-Data-in-Geographic-Atrophy-from-Avacincaptad-Pegol-GATHER-Trials","journal-title":"Business Wire"},{"key":"e_1_3_4_70_1","article-title":"FDA approval for IZERVAYTM (avacincaptad pegol intravitreal solution), a New treatment for geographic atrophy [Internet]","author":"Astellas Pharma. Iveric Bio Receives U.S","year":"2023","unstructured":"Astellas Pharma. Iveric Bio Receives U.S. FDA approval for IZERVAYTM (avacincaptad pegol intravitreal solution), a New treatment for geographic atrophy [Internet]. Astellas. 2023 [cited 2023 Aug 26]. Available from: https:\/\/www.astellas.com\/en\/news\/28281","journal-title":"Astellas"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.05.006"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddab086"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213462"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2014.07.017"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.491"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8425"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000377"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01842-1"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000359"},{"key":"e_1_3_4_80_1","article-title":"Preventing progression of dry age-related macular degeneration (AMD): Hemera Biosciences\u2019 dry AMD drug succeeds in Phase I safety study [Internet]","author":"Tufts Office of the Vice Provost for Research","year":"2020","unstructured":"Tufts Office of the Vice Provost for Research. Preventing progression of dry age-related macular degeneration (AMD): Hemera Biosciences\u2019 dry AMD drug succeeds in Phase I safety study [Internet]. Tufts University. 2020 [cited 2023 Apr 30]. Available from: https:\/\/viceprovost.tufts.edu\/news\/preventing-progression-dry-age-related-macular-degeneration-amd","journal-title":"Tufts University"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.20.10996"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.02.005"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep22889"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.01.006"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67292-z"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50420-9"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10449"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1814014116"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2758"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.5867"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100154"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-359646"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.11.003"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2011.0212"},{"key":"e_1_3_4_95_1","first-page":"2295","article-title":"GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD)","volume":"61","author":"Ellis S","year":"2020","unstructured":"Ellis S, Buchberger A, Holder J, et al. GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD). Invest Ophthalmol Visual Sci. 2020;61:2295.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712572"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf1443"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.1544"},{"key":"e_1_3_4_99_1","first-page":"187","article-title":"Oral administration of the complement factor D inhibitor danicopan (ALXN2040) in preclinical studies demonstrates high and sustained drug concentrations in posterior ocular tissues for the potential treatment of geographic atrophy","volume":"62","author":"Boyer D","year":"2021","unstructured":"Boyer D, Rivera J, Ko Y-P, et al. Oral administration of the complement factor D inhibitor danicopan (ALXN2040) in preclinical studies demonstrates high and sustained drug concentrations in posterior ocular tissues for the potential treatment of geographic atrophy. Invest Ophthalmol Visual Sci. 2021;62:187.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_100_1","first-page":"4305","article-title":"Development of IONIS-FB-LRx to treat geographic atrophy associated with AMD","volume":"61","author":"Jaffe GJ","year":"2020","unstructured":"Jaffe GJ, Sahni J, Fauser S, et al. Development of IONIS-FB-LRx to treat geographic atrophy associated with AMD. Invest Ophthalmol Visual Sci. 2020;61:4305.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.2.3"},{"key":"e_1_3_4_102_1","article-title":"Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function [Internet]","author":"Annexon Inc","year":"2023","unstructured":"Annexon Inc. Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function [Internet]. Annexon Biosci. 2023 [cited 2023 Aug 31]. Available from: https:\/\/ir.annexonbio.com\/news-releases\/news-release-details\/annexon-topline-data-archer-phase-2-trial-anx007-geographic\/.","journal-title":"Annexon Biosci"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2023.2257604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T16:19:26Z","timestamp":1727194766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2023.2257604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":100,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,11,22]]}},"alternative-id":["10.1080\/14656566.2023.2257604"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2023.2257604","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}